Genscript Biotech (HKG:1548) expects to swing to profit in the first half of 2025, according to a Hong Kong bourse filing Tuesday.
The biopharmaceutical company is estimating $175.4 million to $204.6 million in profit before tax, compared to a loss of $127.9 million in the year-ago period.
Genscript expects to post its financial results by the end of August.